|  Help  |  About  |  Contact Us

Publication : SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis.

First Author  Weisser SB Year  2011
Journal  J Leukoc Biol Volume  90
Issue  3 Pages  483-92
PubMed ID  21685246 Mgi Jnum  J:175715
Mgi Id  MGI:5287076 Doi  10.1189/jlb.0311124
Citation  Weisser SB, et al. (2011) SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis. J Leukoc Biol 90(3):483-92
abstractText  mvarphi are heterogeneous in their functions, and although it is clear that inflammatory mvarphi contribute to inflammation in IBDs, multiple lines of evidence suggest that M2a mvarphi may offer protection during intestinal inflammation. In vivo SHIP-deficient mouse mvarphi are M2a so SHIP-deficient mice provide a unique genetic model of M2a mvarphi. Based on this, this study tested the hypothesis that SHIP-deficient, M2a mvarphi protect mice from intestinal inflammation. The objectives were to compare the susceptibility of SHIP+/+ and SHIP-/- littermates with DSS-induced intestinal inflammation and to determine whether protection was mvarphi-mediated and whether protection could be transferred to a susceptible host. We have found that SHIP-/- mice are protected during DSS-induced intestinal inflammation. SHIP-/- mice have delayed rectal bleeding and reduced weight loss, disruption of intestinal architecture, and immune cell infiltration during DSS-induced colitis relative to their WT littermates. Using liposome depletion of mvarphi, we found that SHIP-/- mouse protection was indeed mvarphi-mediated. Finally, we determined that SHIP-/- mvarphi-mediated protection could be conferred to susceptible WT mice by adoptive transfer of M2a mvarphi derived ex vivo. This study supports our hypothesis by demonstrating that SHIP-deficient, M2a mvarphi are protective in this murine model of acute intestinal inflammation. Adoptive transfer of M2a mvarphi to patients with IBDs offers a promising, new strategy for treatment that may be particularly useful in patients who are otherwise refractory to conventional therapies.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Bio Entities

Trail: Publication

0 Expression